HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population

Thyroid ◽  
2016 ◽  
Vol 26 (5) ◽  
pp. 667-671 ◽  
Author(s):  
Ali S. Alzahrani ◽  
Avaniyapuram Kannan Murugan ◽  
Ebtesam Qasem ◽  
Hindi Al-Hindi
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Middle Eastern ◽  
Gene Mutations ◽  
Eastern Population ◽  
Medullary Thyroid ◽  
Middle Eastern Population

scholarly journals Current status of the prognostic molecular markers in medullary thyroid carcinoma

2020 ◽  
Vol 9 (12) ◽  
pp. R251-R263
Author(s):  
Malgorzata Oczko-Wojciechowska ◽  
Agnieszka Czarniecka ◽  
Tomasz Gawlik ◽  
Barbara Jarzab ◽  
Jolanta Krajewska
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Tnm Classification ◽  
Gene Mutations ◽  
Distant Metastases ◽  
Tumor Stage ◽  
Current Status ◽  
Medullary Thyroid ◽  
Long Term Follow Up

Medullary thyroid cancer (MTC) is a rare thyroid malignancy, which arises from parafollicular C-cells. It occurs in the hereditary or sporadic form. Hereditary type is a consequence of activation of the RET proto-oncogene by germline mutations, whereas about 80% of sporadic MTC tumors harbor somatic, mainly RET or rarely RAS mutations. According to the current ATA guidelines, a postoperative MTC risk stratification and long-term follow-up are mainly based on histopathological data, including tumor stage, the presence of lymph node and/or distant metastases (TNM classification), and serum concentration of two biomarkers: calcitonin (Ctn) and carcinoembryonic antigen (CEA). The type of RET germline mutation also correlates with MTC clinical characteristics. The most common and the best known RET mutation in sporadic MTC, localized at codon 918, is related to a more aggressive MTC course and poorer survival. However, even if histopathological or clinical features allow to predict a long-term prognosis, they are not sufficient to select the patients showing aggressive MTC courses requiring immediate treatment or those, who are refractory to different therapeutic methods. Besides the RET gene mutations, there are currently no other reliable molecular prognostic markers. This review summarizes the present data of genomic investigation on molecular prognostic factors in medullary thyroid cancer.

scholarly journals Erratum: Corrigendum: Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Malgorzata Oczko-Wojciechowska ◽  
Michal Swierniak ◽  
Jolanta Krajewska ◽  
Malgorzata Kowalska ◽  
Monika Kowal ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Gene Mutations ◽  
Medullary Thyroid ◽  
Ret Gene ◽  
The Status

Abstract #1101 The Value of Calcitonin Calcium Stimulation Test Levels as Predictors of Medullary Thyroid Cancer.

2018 ◽  
Vol 24 ◽  
pp. 273-274
Author(s):  
Corin Badiu ◽  
Mara Baet ◽  
Ruxandra Dobrescu ◽  
Andra Caragheorgheopol ◽  
Corneci Cristina
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Stimulation Test ◽  
Medullary Thyroid ◽  
Calcium Stimulation

Immunoscintigraphy in Medullary Thyroid Cancer Using an 123I- or 111ln-Labelled Monoclonal Anti-CEA Antibody Fragment

1986 ◽  
Vol 25 (06) ◽  
pp. 227-231 ◽  
Author(s):  
Chr. Eilles ◽  
W. Spiegel ◽  
W. Becker ◽  
W. Börner ◽  
Chr. Reiners
Keyword(s):  
Bone Marrow ◽  
Thyroid Cancer ◽  
Potassium Iodide ◽  
Medullary Thyroid Cancer ◽  
Elevated Serum ◽  
Antibody Fragment ◽  
Special Importance ◽  
Medullary Thyroid ◽  
Medullary Cancer ◽  
Serum Cea

The monoclonal anti-CEA F(ab’)2 fragment MAb BW 431/31, labelled with 123I or111 In, was used for immunoscintigraphy (IS) in 9 patients with medullary cancer of the thyroid (CCC). The results of 11 studies lead to the following conclusions: 1) When using radioiodine as a label for MAb in IS, potassium iodide is absolutely necessary to block the thyroid which is of special importance in patients with thyroid cancer; 2) Preinjection of “cold” MAb reduces the relatively high unspecific uptake (especially in bone marrow) of MAb BW 431/31, which is of special importance for the antibody labelled with 111 In; 3) IS with MAb BW 413/31 in patients with CCC and elevated serum CEA is positive only in cases with large secondaries; and 4) In patients with CCC and several manifestations of secondaries, only a single (large) metastasis may be apparent.

Sign in / Sign up

Export Citation Format

Share Document